Andrew Hooker
Professor vid Institutionen för farmaci; Farmakometri
- Mobiltelefon:
- 070-167 90 48
- E-post:
- andrew.hooker@farmaci.uu.se
- Besöksadress:
- Biomedicinskt Centrum BMC, Husargatan 3
752 37 Uppsala - Postadress:
- Box 580
751 23 UPPSALA
Ladda ned kontaktuppgifter för Andrew Hooker vid Institutionen för farmaci; Farmakometri
- ORCID:
- 0000-0002-2676-5912
Mer information visas för dig som medarbetare om du loggar in.
Kort presentation
My research is focused on pharmacometrics (PKPD). Topics include optimal experimental design, methodological problems associated with building and evaluating PKPD models, modeling discrete data, and the development and use of PKPD models in a range of therapeutic areas and drug classes including cancer, addiction, PET, progressive disorders, and biologics. I also develop a number of software programs for pharmacometrics.
I teach courses in statistics, drug development, and pharmacometrics.
Nyckelord
- free and open source software
- nonlinear mixed-effects models
- optimal design
- optimal experimental design
- pharmacometrics
- pkpd
- population models
Publikationer
Urval av publikationer
- The Role of Model Master Files for Sharing, Acceptance, and Communication with FDA (2024)
- Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials (2023)
- Establishing the suitability of model-integrated evidence to demonstrate bioequivalence for long-acting injectable and implantable drug products (2023)
- Tutorial for $DESIGN in NONMEM (2021)
- Metaheuristics for pharmacometrics (2021)
- Public Workshop Summary Report on Fiscal Year 2021 Generic Drug Regulatory Science Initiatives (2021)
- Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia (2021)
- Pharmacometrics meets statistics-A synergy for modern drug development (2021)
- Model-Informed Drug Development for Long-Acting Injectable Products (2021)
- Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis (2020)
- Saddle-Reset for Robust Parameter Estimation and Identifiability Analysis of Nonlinear Mixed Effects Models (2020)
- Item Response Theory Modeling of the International Prostate Symptom Score in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia (2020)
- Optimizing Dose-Finding Studies for Drug Combinations Based on Exposure-Response Models (2019)
- Reduced and optimized trial designs for drugs described by a target mediated drug disposition model (2018)
- A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim (2018)
- Model-Informed Drug Development and Review for Generic Products (2018)
- Feasibility of Exposure-Response Analyses for Clinical Dose-Ranging Studies of Drug Combinations (2018)
- Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs (2018)
- Implementing Optimal Designs for Dose-Response Studies Through Adaptive Randomization for a Small Population Group (2018)
- Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes (2018)
- Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection (2017)
- Assessing robustness of designs for random effects parameters for nonlinear mixed-effects models (2017)
- Advanced Methods for Dose and Regimen Finding During Drug Development (2017)
- Model Evaluation of Continuous Data Pharmacometric Models (2017)
- The effect of using a robust optimality criterion in model based adaptive optimization. (2017)
- Preconditioning of Nonlinear Mixed Effects Models for Stabilisation of Variance-Covariance Matrix Computations (2016)
- Accelerating Monte Carlo power studies through parametric power estimation (2016)
- Improved precision of exposure-response relationships by optimal dose-selection. Examples from studies of receptor occupancy using PET and dose finding for neuropathic pain treatment (2015)
- Methods and software tools for design evaluation for population pharmacokinetics-pharmacodynamics studies (2015)
- Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model (2014)
- Improved Utilization of ADAS-cog Assessment Data through Item Response Theory based Pharmacometric Modeling (2014)
- Modeling and Simulation Workbench for NONMEM (2013)
- PopED (2012)
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models (2011)
- Optimal Design in Population Kinetic Experiments by Set-Valued Methods (2011)
- Adaptive-Optimal Design in PET Occupancy Studies (2010)
- Conditional weighted residuals (CWRES) (2007)
- Robust population pharmacokinetic experiment design. (2005)
- Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments. (2005)
Senaste publikationer
- The Role of Model Master Files for Sharing, Acceptance, and Communication with FDA (2024)
- Generation and application of avatars in pharmacometric modelling (2023)
- Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials (2023)
- Establishing the suitability of model-integrated evidence to demonstrate bioequivalence for long-acting injectable and implantable drug products (2023)
- How to Analyze Continuous and Discrete Repeated Measures in Small-Sample Cross-Over Trials? (2023)
Alla publikationer
Artiklar
- The Role of Model Master Files for Sharing, Acceptance, and Communication with FDA (2024)
- Generation and application of avatars in pharmacometric modelling (2023)
- Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials (2023)
- Establishing the suitability of model-integrated evidence to demonstrate bioequivalence for long-acting injectable and implantable drug products (2023)
- How to Analyze Continuous and Discrete Repeated Measures in Small-Sample Cross-Over Trials? (2023)
- Tutorial for $DESIGN in NONMEM (2021)
- Metaheuristics for pharmacometrics (2021)
- Public Workshop Summary Report on Fiscal Year 2021 Generic Drug Regulatory Science Initiatives (2021)
- Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia (2021)
- Pharmacometrics meets statistics-A synergy for modern drug development (2021)
- Model-Informed Drug Development for Long-Acting Injectable Products (2021)
- Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis (2020)
- Saddle-Reset for Robust Parameter Estimation and Identifiability Analysis of Nonlinear Mixed Effects Models (2020)
- Item Response Theory Modeling of the International Prostate Symptom Score in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia (2020)
- Optimizing Dose-Finding Studies for Drug Combinations Based on Exposure-Response Models (2019)
- Reduced and optimized trial designs for drugs described by a target mediated drug disposition model (2018)
- A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim (2018)
- Model-Informed Drug Development and Review for Generic Products (2018)
- Feasibility of Exposure-Response Analyses for Clinical Dose-Ranging Studies of Drug Combinations (2018)
- Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs (2018)
- Implementing Optimal Designs for Dose-Response Studies Through Adaptive Randomization for a Small Population Group (2018)
- Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes (2018)
- The Standard Output (2018)
- Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection (2017)
- Assessing robustness of designs for random effects parameters for nonlinear mixed-effects models (2017)
- Advanced Methods for Dose and Regimen Finding During Drug Development (2017)
- Model Evaluation of Continuous Data Pharmacometric Models (2017)
- Model Description Language (MDL) (2017)
- The effect of using a robust optimality criterion in model based adaptive optimization. (2017)
- Maturation of Oxycodone Pharmacokinetics in Neonates and Infants (2017)
- A diagnostic tool for population models using non-compartmental analysis (2016)
- PopED lite: an optimal design software for preclinical pharmacokinetic and pharmacodynamic studies (2016)
- Preconditioning of Nonlinear Mixed Effects Models for Stabilisation of Variance-Covariance Matrix Computations (2016)
- The effect of Fisher information matrix approximation methods in population optimal design calculations (2016)
- Accelerating Monte Carlo power studies through parametric power estimation (2016)
- Improved precision of exposure-response relationships by optimal dose-selection. Examples from studies of receptor occupancy using PET and dose finding for neuropathic pain treatment (2015)
- Estimation of drug receptor occupancy when non-displaceable binding differs between brain regions (2015)
- Methods and software tools for design evaluation for population pharmacokinetics-pharmacodynamics studies (2015)
- Pharmacometrics Markup Language (PharmML) (2015)
- Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model (2014)
- Evaluation of Bias, Precision, Robustness and Runtime for Estimation Methods in NONMEM 7 (2014)
- Simultaneous pharmacokinetic modeling of alkylresorcinols and their main metabolites indicates dual absorption mechanisms and enterohepatic elimination in humans (2014)
- Improved Utilization of ADAS-cog Assessment Data through Item Response Theory based Pharmacometric Modeling (2014)
- Population pharmacometrics in support of analgesics studies (2014)
- Simultaneous optimal experimental design for in vitro binding parameter estimation (2013)
- Modeling and Simulation Workbench for NONMEM (2013)
- A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066-Estimating occupancy in the absence of a reference region (2013)
- Chain length of dietary alkylresorcinols affects their in vivo elimination kinetics in rats (2013)
- Current Use and Developments Needed for Optimal Design in Pharmacometrics (2013)
- Optimizing disease progression study designs for drug effect discrimination (2013)
- Application of the Optimal Design Approach to Improve a Pretransplant Drug Dose Finding Design for Ciclosporin (2012)
- Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers (2012)
- Ethically Attractive Dose-Finding Designs for Drugs With a Narrow Therapeutic Index (2012)
- Serial correlation in optimal design for nonlinear mixed effects models (2012)
- PopED (2012)
- Joint Modeling of Efficacy, Dropout, and Tolerability in Flexible-Dose Trials (2012)
- Plasma and Cerebrospinal Fluid Pharmacokinetics of Naproxen in Children (2012)
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models (2011)
- Multinomial Logistic Functions in Markov Chain Models of Sleep Architecture (2011)
- Optimal Design in Population Kinetic Experiments by Set-Valued Methods (2011)
- A Fast Method for Testing Covariates in Population PK/PD Models (2011)
- Optimal experimental design for assessment of enzyme kinetics in a drug discovery screening environment (2011)
- Methodological Comparison of In Vitro Binding Parameter Estimation (2010)
- Plasma and cerebrospinal fluid pharmacokinetics of flurbiprofen in children (2010)
- Adaptive-Optimal Design in PET Occupancy Studies (2010)
- Trial treatment length optimization with an emphasis on disease progression studies (2009)
- Modeling subpopulations with the $MIXTURE subroutine in NONMEM (2009)
- Simultaneous optimal experimental design on dose and sample times (2009)
- Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design (2009)
- Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function (2008)
- Non-Bayesian Knowledge Propagation using Model Model-Based Analysis of Data from Multiple Clinical Studies (2008)
- Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier (2008)
- Conditional weighted residuals (CWRES) (2007)
- Automated identification of axonal growth cones in time-lapse image sequences. (2006)
- Robust population pharmacokinetic experiment design. (2005)
- Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments. (2005)
- POPED, a software for optimal experiment design in population kinetics. (2004)
- An evaluation of population D-optimal designs via pharmacokinetic simulations. (2003)
- Quantitative magnetic resonance imaging analysis of neovasculature volume in carotid atherosclerotic plaque. (2003)
- Classical examination of the Stark effect in hydrogen (1997)
- Evaluation of model-integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods
- Development and comparison of model-integrated evidence approaches for bioequivalence studies with pharmacokinetic endpoints
